Company Contact:Casey LoganChief Business Officer(858) 550-0780 ext. firstname.lastname@example.orgInvestor Contact:Andrew McDonaldLifeSci Advisors LLC646-597-6987Andrew@lifesciadvisors.com
SAN DIEGO, Nov. 07, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the following investor conferences in November: Stifel 2016 Healthcare ConferenceTuesday, November 15, at 3:00 PM EST at the Lotte New York Palace Hotel in New York, NY Jefferies 2016 London Healthcare ConferenceThursday, November 17, at 4:40 PM GMT (11:40 AM EST) at the Waldorf Hilton in London, UK 28 th Annual Piper Jaffray Healthcare ConferenceWednesday, November 30, at 9:30 AM EST at the Lotte New York Palace Hotel in New York, NY To access live webcasts of the presentations, please visit the "Events and Presentation" section within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcasts will be available on the website for 60 days following the events. About TRACON TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. - TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.